Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
News

Direct-to-consumer prescription drug ads getting bolder

Ann Silversides
CMAJ August 21, 2001 165 (4) 462;
Ann Silversides
Toronto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Canada's pharmaceutical companies appear to be pushing the envelope in a bid to pitch their wares directly to Canadian consumers.

Officially, Canada's Food and Drug Act prohibits this direct-to-consumer advertising (DTCA). Although a 1996 Health Canada policy paper defines DTCA as an activity “with the primary aim of stimulating product sales,” advertisements for products such as birth-control pills and erectile-dysfunction drugs now appear regularly in Canadian magazines and on the country's TV screens. They join the cross-border barrage of ads from the US, where DTCA is legal.

Critics aren't amused by the move toward made-in-Canada ads. “I think what's happened, for reasons that aren't entirely clear, is that Health Canada has reinterpreted the law,” says Joel Lexchin, a Toronto doctor who comments frequently on the pharmaceutical industry. “But in a strict reading of the law, these advertisements are illegal.”

Existing legislation prohibits DTCA involving prescription drugs because these drugs cannot be compared with other consumer items, explains Ross Duncan, Health Canada's policy adviser on DTCA. But most of the ads currently appearing on TV, at movie theatres and in magazines is legal, he says.

A 1978 amendment, designed to allow pharmacists to post comparative prices, allows DTCA as long as “the person shall not make any representation other than with respect to the brand name, proper name, price and quantity of the drug.”

Duncan says this means that providing “information” is not illegal, and Health Canada has taken the position that “help-seeking” ads — those that describe a medical condition such as erectile dysfunction and then direct consumers to a doctor, telephone number or Web site — are legal. More controversial are “reminder” or “branded” advertisements, which mention the brand name of the drug but don't say what condition it treats. While critics say they are clearly prohibited advertising, Health Canada maintains that they are legal.

Indeed, Health Canada says the only real problem is mentioning the brand name and the therapeutic use of a drug in the same advertisement. Advertisers have tried to push the envelope, and federal officials did cry foul when Wyeth-Ayerst Canada aired branded television ads for a birth-control pill, Alesse, and then, a few weeks later, aired unbranded ads with the same actors. But it took Health Canada 6 months to inform the company that the campaign “is considered to contravene the Food and Drug Regulations.” No penalties were suggested in the letter, but there was a friendly warning to take this decision in account “when developing future advertisements.” Wyeth-Ayerst subsequently opted to air only advertisements that did not name the product.

Health Canada wrote a stronger letter to Glaxo Wellcome (now GlaxoSmithKline) when advertisements for bupropion (Zyban) ran on TV just after New Year's 2000. “These commercials violate section c.01.044(1) of the regulations. We ask you to immediately suspend broadcast of these commercials until a full review of this activity can be completed,” stated the letter, sent 7 weeks after the first ad was aired.

A defiant GlaxoSmithKline responded that the advertising had in fact been informational programming by CTV — an antismoking vignette about a successful smoking-cessation experience — followed by a “sponsorship statement.” A slightly revised version of the same advertisement/vignette aired on CTV in January 2001. This prompted another Health Canada investigation, but as of mid-May officials would say only that the investigation is “ongoing.”

Advertising prescription drugs directly to consumers “gets in the way of treatment,” says Saskatoon urologist Peter Barrett, the CMA's past president. Drug companies should show doctors why their products are useful, he said in an interview, but pitching drugs directly to patients puts an extra strain on doctors, who must take time to explain why the advertised drugs may be inappropriate.

Meanwhile, the drug and advertising industries are lobbying hard to loosen existing restrictions on DTCA, a move that the CMA opposes. The Food and Drug Act is being opened up for “legislative renewal,” and new draft legislation is expected soon. DTCA is one of the most controversial areas, Duncan says, and one of the few points that has been agreed upon is that there be mandatory pre-clearance of such ads.

As yet there is no official body vetting DTCA before it appears, since such advertising, at least officially, does not exist.

PreviousNext
Back to top

In this issue

CMAJ
Vol. 165, Issue 4
21 Aug 2001
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Direct-to-consumer prescription drug ads getting bolder
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Direct-to-consumer prescription drug ads getting bolder
Ann Silversides
CMAJ Aug 2001, 165 (4) 462;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Direct-to-consumer prescription drug ads getting bolder
Ann Silversides
CMAJ Aug 2001, 165 (4) 462;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA
  • Direct-to-consumer prescription drug advertising in Canada: Permission by default?
  • Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey
  • Google Scholar

More in this TOC Section

  • Resignations at Canada’s drug pricing panel raise independence questions
  • Provinces accept federal health funding deal
  • Feds propose $196B health funding deal with few strings attached
Show more News

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire